Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Infant immune development after in utero exposure to anti-TNF and other immunomodulating drugs
NL-OMON54516Completed
- Sponsor
- HagaZiekenhuis
- Start
- Dec 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Open-label trial of Salcrozine and tocilizumab in inflammatory bowel disease (IBD) and coronavirus disease 2019 (COVID-19) (4 arms), sponsored by HagaZiekenhuis. Primary endpoints: Immunological markers at 12 months and Frequency of infections. Started Dec 2018; status: completed.
02
Drugs
Salcrozinetocilizumab
03
Conditions
inflammatory bowel disease (IBD)coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NL-OMON54516.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54516.